Overview

AMP002 Phase III Contraceptive Study

Status:
Completed

Trial end date:
2018-11-29

Target enrollment:

Participant gender:

Summary

This is a single-arm, open-label, Phase III study in approximately 100 sites in the United States (US) over seven cycles of use in women aged 18 to 35 years who are at risk of pregnancy.

Phase:

Phase 3

Details

Lead Sponsor:

Evofem Inc.

Collaborator:

Parexel

Treatments:

Contraceptive Agents